These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36345163)

  • 1. Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers.
    Mori T; Okamoto Y; Mu A; Ide Y; Yoshimura A; Senda N; Inagaki-Kawata Y; Kawashima M; Kitao H; Tokunaga E; Miyoshi Y; Ohsumi S; Tsugawa K; Ohta T; Katagiri T; Ohtsuru S; Koike K; Ogawa S; Toi M; Iwata H; Nakamura S; Matsuo K; Takata M
    Cancer Med; 2023 Mar; 12(6):6594-6602. PubMed ID: 36345163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients.
    Hira A; Yabe H; Yoshida K; Okuno Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Nakamura J; Kojima S; Ogawa S; Matsuo K; Takata M; Yabe M
    Blood; 2013 Oct; 122(18):3206-9. PubMed ID: 24037726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of disease model iPSCs derived from patients with a novel Fanconi anemia-like IBMFS ADH5/ALDH2 deficiency.
    Mu A; Hira A; Niwa A; Osawa M; Yoshida K; Mori M; Okamoto Y; Inoue K; Kondo K; Kanemaki MT; Matsuda T; Ito E; Kojima S; Nakahata T; Ogawa S; Tanaka K; Matsuo K; Saito MK; Takata M
    Blood; 2021 Apr; 137(15):2021-2032. PubMed ID: 33512438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic analysis of Japanese patients with Fanconi anemia: novel findings].
    Mori M; Yabe H; Yabe M; Takata M
    Rinsho Ketsueki; 2019; 60(6):691-701. PubMed ID: 31281162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phenotype and clinical course of Japanese Fanconi Anaemia infants is influenced by patient, but not maternal ALDH2 genotype.
    Yabe M; Yabe H; Morimoto T; Fukumura A; Ohtsubo K; Koike T; Yoshida K; Ogawa S; Ito E; Okuno Y; Muramatsu H; Kojima S; Matsuo K; Hira A; Takata M
    Br J Haematol; 2016 Nov; 175(3):457-461. PubMed ID: 27377053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde dehydrogenase 2 in aplastic anemia, Fanconi anemia and hematopoietic stem cells.
    Van Wassenhove LD; Mochly-Rosen D; Weinberg KI
    Mol Genet Metab; 2016 Sep; 119(1-2):28-36. PubMed ID: 27650066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new Fanconi anemia-like disorder, aldehyde degradation deficiency syndrome: two defense mechanisms working together for the genome and hematopoiesis].
    Takata M
    Rinsho Ketsueki; 2023; 64(7):639-645. PubMed ID: 37544724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
    Tacconi EM; Lai X; Folio C; Porru M; Zonderland G; Badie S; Michl J; Sechi I; Rogier M; Matía García V; Batra AS; Rueda OM; Bouwman P; Jonkers J; Ryan A; Reina-San-Martin B; Hui J; Tang N; Bruna A; Biroccio A; Tarsounas M
    EMBO Mol Med; 2017 Oct; 9(10):1398-1414. PubMed ID: 28729482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single nucleotide polymorphism in the ALDH2 gene modifies the risk of esophageal squamous cell carcinoma in BRCA2 p.K3326* carriers.
    Zamani N; Szymiczek A; Shakeri R; Poustchi H; Pourshams A; Narod S; Malekzadeh R; Akbari MR
    PLoS One; 2023; 18(11):e0292611. PubMed ID: 37943872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2.
    Kluźniak W; Szymiczek A; Rodrigue A; Wokołorczyk D; Rusak B; Stempa K; Huzarski T; Gronwald J; Lubiński J; Zamani N; Zhang S; Masson JY; Narod SA; ; Cybulski C; Akbari MR
    JCO Precis Oncol; 2022 Apr; 6():e2100450. PubMed ID: 35442721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of complementation group, ALDH2 genotype, and clonal abnormalities with hematological outcome in Japanese patients with Fanconi anemia.
    Yabe M; Koike T; Ohtsubo K; Imai E; Morimoto T; Takakura H; Koh K; Yoshida K; Ogawa S; Ito E; Okuno Y; Muramatsu H; Kojima S; Matsuo K; Mori M; Hira A; Takata M; Yabe H
    Ann Hematol; 2019 Feb; 98(2):271-280. PubMed ID: 30368588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The frequency and pathogenicity of BRCA1 and BRCA2 variants in the general Japanese population.
    Idogawa M; Mariya T; Tanaka Y; Saito T; Nakase H; Tokino T; Sakurai A
    J Hum Genet; 2024 May; 69(5):225-230. PubMed ID: 38409497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers.
    Cheung RS; Taniguchi T
    Int J Hematol; 2017 Sep; 106(3):335-344. PubMed ID: 28631178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
    Keupp K; Hampp S; Hübbel A; Maringa M; Kostezka S; Rhiem K; Waha A; Wappenschmidt B; Pujol R; Surrallés J; Schmutzler RK; Wiesmüller L; Hahnen E
    Mol Genet Genomic Med; 2019 Sep; 7(9):e863. PubMed ID: 31347298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.